Heart Disease Community
Atenolol for LQT?
About This Community:

This patient support community is for discussions relating to angina, angioplasty, arrhythmia, bypass surgery, cardiomyopathy, coronary artery disease, defibrillator, heart attack, heart disease, mitral valve, pacemaker, PAD, stenosis, and stress tests.

Font Size:
A
A
A
Background:
Blank
Blank
Blank
Blank Blank

Atenolol for LQT?

Dear Cleveland MD:

Atenolol seemed to cause higher mortality in LQT pediatric patients in older literature.

More recently, another article points out the inferiority of Atenolol:

Abstract
Beta-blocker therapy is one of the principal therapies for congenital long-QT syndrome (LQTS). However, breakthrough cardiac events occur while being treated with beta-blockers. We sought to determine the frequency of and clinical correlates underlying beta-blocker therapy failures in genotyped, symptomatic LQTS probands. The medical records were analyzed only for genotyped LQTS probands who presented with a LQTS-attributable clinical event and were receiving beta-blocker therapy. The study cohort comprised 28 such patients: 18 KCNQ1/KVLQT1(LQT1), 7 KCNH2/HERG (LQT2), and 3 SCN5A (LQT3). The prescribed beta-blocker was atenolol (12), propranolol (10), metoprolol (4), and nadolol (2). Beta-blocker therapy failure was defined as breakthrough cardiac events including syncope, aborted cardiac arrest (ACA), appropriate implantable cardioverter-defibrillator (ICD) therapy, or sudden death occurring while on beta-blocker therapy. During a median follow-up of 46 months, 7/28 (25%) LQTS probands experienced a total of 15 breakthrough cardiac events. Their initial presentation was ACA (3), bradycardia during infancy (2), and syncope (2). The underlying genotype was KVLQT1 (6) and HERG (1). Two breakthroughs were attributed to noncompliance. Of the 13 breakthroughs occurring while compliant, 10 occurred with atenolol and 3 with propranolol (p = 0.03). In this study cohort, one-fourth of genotyped LQTS probands failed beta-blocker therapy. Treatment with atenolol, young age at diagnosis, initial presentation with ACA, KVLQT1 genotype, and noncompliance may be important factors underlying beta-blocker therapy failures.

Why is Atenolol still being used?

Thanks


This discussion is related to Long QT Syndrome.
Related Discussions
Post a Comment
To
MedHelp Health Answers
Recent Activity
Avatar_m_tn
Blank
ill13632 severe disease Comment
Apr 14
1317224_tn?1378708734
Blank
MaryLL I'm feeling good 16 months ... Comment
Apr 13
1317224_tn?1378708734
Blank
MaryLL uploaded new photos
Apr 13
Blank
BloodPressure Tracker
Monitor Your Blood Pressure
Start Tracking Now
Heart Disease Community Resources
RSS Expert Activity
242532_tn?1269553979
Blank
Emotional Eaters: How to Silence Yo...
Mar 26 by Roger Gould, M.D.Blank
1344197_tn?1392822771
Blank
Vaginal vs. Laparoscopic Hysterecto...
Feb 19 by J. Kyle Mathews, MD, DVMBlank
1684282_tn?1350782543
Blank
The Death by Heroin
Feb 03 by Julia M Aharonov, DOBlank
Top Heart Disease Answerers
976897_tn?1379171202
Blank
ed34
watford, United Kingdom
63984_tn?1385441539
Blank
Flycaster305
97303, OR
159619_tn?1318997813
Blank
erijon
Salt Lake City, UT
Avatar_f_tn
Blank
skydnsr
212161_tn?1391090750
Blank
heartfluttersflyawayplz
hoschton, GA
612551_tn?1247839157
Blank
Jerry_NJ
NJ